Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label study of M9466 alone or in combination in advanced solid tumors
jRCT2031240255Phase 1Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of M9466 in Nonhematologic neoplasms, prostate cancer (PCa) and epithelial ovarian cancer (EOC) (5 arms), sponsored by Merck KGaA. Primary endpoints: Treatment-emergent adverse events and treatment-related adverse events, Dose-limiting-toxicity-like events and 1 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
M9466
03
Conditions
Nonhematologic neoplasmsprostate cancer (PCa)epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on jRCT2031240255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240255.